165 related articles for article (PubMed ID: 21035488)
1. Physiology and pathology of nuclear phospholipase C β1.
Cocco L; Follo MY; Faenza I; Fiume R; Ramazzotti G; Weber G; Martelli AM; Manzoli FA
Adv Enzyme Regul; 2011; 51(1):2-12. PubMed ID: 21035488
[TBL] [Abstract][Full Text] [Related]
2. Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia.
Cocco L; Manzoli L; Palka G; Martelli AM
Adv Enzyme Regul; 2005; 45():126-35. PubMed ID: 16024064
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide-specific phospholipase C beta1 signal transduction in the nucleus.
Fiume R; Teti G; Faenza I; Cocco L
Methods Mol Biol; 2010; 645():143-64. PubMed ID: 20645187
[TBL] [Abstract][Full Text] [Related]
4. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells.
Cocco L; Follo MY; Faenza I; Bavelloni A; Billi AM; Martelli AM; Manzoli L
Adv Enzyme Regul; 2007; 47():2-9. PubMed ID: 17335878
[No Abstract] [Full Text] [Related]
5. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
7. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
[TBL] [Abstract][Full Text] [Related]
8. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation.
Faenza I; Billi AM; Follo MY; Fiume R; Martelli AM; Cocco L; Manzoli L
Anticancer Res; 2005; 25(3B):2039-41. PubMed ID: 16158942
[TBL] [Abstract][Full Text] [Related]
9. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
11. Nuclear PI-PLCβ1: an appraisal on targets and pathology.
Follo MY; Faenza I; Piazzi M; Blalock WL; Manzoli L; McCubrey JA; Cocco L
Adv Biol Regul; 2014 Jan; 54():2-11. PubMed ID: 24296032
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Inositide Signaling Via Phospholipase C.
Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
[TBL] [Abstract][Full Text] [Related]
13. Nuclear phospholipase C: involvement in signal transduction.
Manzoli L; Martelli AM; Billi AM; Faenza I; Fiume R; Cocco L
Prog Lipid Res; 2005 Jul; 44(4):185-206. PubMed ID: 15896848
[TBL] [Abstract][Full Text] [Related]
14. Regulation of nuclear phospholipase C activity.
Manzoli L; Billi AM; Martelli AM; Cocco L
Acta Biochim Pol; 2004; 51(2):391-5. PubMed ID: 15218536
[TBL] [Abstract][Full Text] [Related]
15. Nuclear inositol lipid cycle: a new central intermediary in signal transduction.
Manzoli L; Gilmour RS; Martelli AM; Billi AM; Cocco L
Anticancer Res; 1996; 16(6A):3283-6. PubMed ID: 9042301
[TBL] [Abstract][Full Text] [Related]
16. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
17. Nuclear inositide specific phospholipase C signalling - interactions and activity.
Faenza I; Fiume R; Piazzi M; Colantoni A; Cocco L
FEBS J; 2013 Dec; 280(24):6311-21. PubMed ID: 23890371
[TBL] [Abstract][Full Text] [Related]
18. Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.
Mongiorgi S; Follo MY; Clissa C; Giardino R; Fini M; Manzoli L; Ramazzotti G; Fiume R; Finelli C; Cocco L
Curr Top Microbiol Immunol; 2012; 362():235-45. PubMed ID: 23086421
[TBL] [Abstract][Full Text] [Related]
19. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
[TBL] [Abstract][Full Text] [Related]
20. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
